---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-244963"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2021-08-13T23:59:59+00:00"
generated_at: "2026-06-29T10:59:01.737726+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Corcept Therapeutics appoints William Guyer as CDO; CMO Andreas Grauer departs

## Summary
- Andreas Grauer separated as CMO effective Aug 10, 2021, becomes senior medical advisor to assist transition.
- William Guyer, formerly SVP at Gilead Sciences, appointed CDO effective Aug 16, 2021.
- Guyer brings ~30 years of experience; led global Medical Affairs at Gilead, involved in multiple drug launches.
- Separation agreement provides Grauer one-year salary continuation, COBRA coverage, and quarterly housing allowance.

## SEC filing metadata
- accession: 0001193125-21-244963
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2021-08-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312521244963/0001193125-21-244963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312521244963/d552481d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-244963
- JSON: https://secwatch.observer/filing/0001193125-21-244963.json
- Plain text: https://secwatch.observer/filing/0001193125-21-244963.txt

## Key facts
- Executive change
  Andreas Grauer changed role as senior medical advisor at CORCEPT THERAPEUTICS INC.
  - Action: agreed to serve as senior medical advisor
  - Role: senior medical advisor
  source text: On August 10, 2021, Andreas Grauer, M.D. separated from his position as Chief Medical Officer of Corcept Therapeutics Incorporated (the “Company”). Dr. Grauer has agreed to serve as a senior medical advisor to the Company to assist with its development programs and to help transition his responsibilities to the Company’s Chief Development Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000119312521244963/0001193125-21-244963-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.